Overview

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
Efficacy and Safety of Locoregional treatments Combined With PD-1 Inhibitor in Patients With Unresectable Hepatocellular Carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Collaborator:
Innovent Biologics (Suzhou) Co. Ltd.
Treatments:
Chlorotrianisene